Abstract
Convalescent plasma is currently one of the leading treatments for COVID-19, but there is a paucity of data identifying therapeutic efficacy. A comprehensive analysis of the antibody responses in potential plasma donors and an understanding of the clinical and demographic factors that drive variant antibody responses is needed. Among 126 potential convalescent plasma donors, the humoral immune response was evaluated by a SARS-CoV-2 virus neutralization assay using Vero-E6-TMPRSS2 cells, commercial IgG and IgA ELISA to Spike (S) protein S1 domain (Euroimmun), IgA, IgG and IgM indirect ELISAs to the full-length S or S-receptor binding domain (S-RBD), and an IgG avidity assay. Multiple linear regression and predictive models were utilized to assess the correlations between antibody responses with demographic and clinical characteristics. IgG titers were greater than either IgM or IgA for S1, full length S, and S-RBD in the overall population. Of the 126 plasma samples, 101 (80%) had detectable neutralizing titers. Using neutralization titer as the reference, the sensitivity of the IgG ELISAs ranged between 95-98%, but specificity was only 20-32%. Male sex, older age, and hospitalization with COVID-19 were all consistently associated with increased antibody responses across the serological assays. Neutralizing antibody titers were reduced over time in contrast to overall antibody responses. There was substantial heterogeneity in the antibody response among potential convalescent plasma donors, but sex, age and hospitalization emerged as factors that can be used to identify individuals with a high likelihood of having strong antiviral antibody levels.
One Sentence Summary There is substantial heterogeneity in the antibody response to SARS-CoV-2 infection, with greater antibody responses being associated with male sex, advancing age, and hospitalization with COVID-19.
Competing Interest Statement
EMB reports personal fees and non-financial support from Terumo BCT, personal fees and non-financial support from Grifols Diagnostics Solutions, outside of the submitted work. EMB is a member of the United States Food and Drug Administration (FDA) Blood Products Advisory Committee. Any views or opinions that are expressed in this manuscript are that of the author, based on his own scientific expertise and professional judgment and do not necessarily represent the views of either the Blood Products Advisory Committee or the formal position of FDA, and also do not bind or otherwise obligate or commit either Advisory Committee or the Agency to the views expressed.
Funding Statement
This work was supported in part by NIH Specialized Center of Research Excellence U54AG062333 (S.L.K, A.P., H-S.P, J.S.); NIH Center of Excellence in Influenza Research and Surveillance HHSN272201400007C (A.P., K.L., S.L.K., R.L.U.); T32A1007417 Molecular and Cellular Basis of Infectious Diseases (R.L.U.); National Institute of Allergy and Infectious Diseases (NIAID) AI052733 and AI15207 (A.C.); NIAID R01AI120938 and R01AI128779 (A.A.R.T); the Division of Intramural Research, NIAID (O.L., T.Q.); National Heart Lung and Blood Institute 1K23HL151826-01 (E.B.M) and HL059842 (A.C.). Bloomberg Philanthropies (A.C.); Department of Defense W911QY2090012 (A.C. and D.S.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Johns Hopkins University School of Medicine Institutional Review Board reviewed and approved the sample collection and overall study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† co-senior authors
Data Availability
All data are contained in the manuscript.
